These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27618361)

  • 41. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
    J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Positron emission tomography with 18F-FDG compared with proliferative activity of tumor cells in different subtypes of non-Hodgkin lymphoma].
    Tiutin LA; Khodzsibekova MM; Pozharisskiĭ KM; Mukhina MS; Kostenikov NA; Il'in NV
    Vopr Onkol; 2011; 57(6):748-52. PubMed ID: 22416392
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.
    Dana BW; Dahlberg S; Nathwani BN; Chase E; Coltman C; Miller TP; Fisher RI
    J Clin Oncol; 1993 Apr; 11(4):644-51. PubMed ID: 8478660
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A single unit lymphoma experience: outcome in a Cape Town academic centre.
    Wood L; Robinson R; Gavine L; Juritz J; Jacobs P
    Transfus Apher Sci; 2007 Aug; 37(1):93-102. PubMed ID: 17931976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
    Schöder H; Noy A; Gönen M; Weng L; Green D; Erdi YE; Larson SM; Yeung HW
    J Clin Oncol; 2005 Jul; 23(21):4643-51. PubMed ID: 15837966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PET imaging today: contribution to the initial staging and prognosis of patients with non-Hodgkin's lymphomas.
    Sattar T; Griffeth LK; Latifi HR; Glass J; Munker R; Lilien DL
    J La State Med Soc; 2006; 158(4):193-201. PubMed ID: 17022364
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Results of the cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) +/- bleomycin treatment and evaluation of prognostic factors in aggressive lymphomas in Turkey.
    Dinçol D; Akbulut H; Içli F; Samur M; Karaoğuz H; Demirkazik A; Cay F
    Oncology; 1997; 54(5):376-9. PubMed ID: 9260598
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary lymphoma of the kidney. Report of a case and update of the literature.
    Porcaro AB; D'Amico A; Novella G; Curti P; Ficarra V; Antoniolli SZ; Martignoni G; Matteo B; Malossini G
    Arch Ital Urol Androl; 2002 Mar; 74(1):44-7. PubMed ID: 12053451
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
    Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection.
    Levine AM; Sadeghi S; Espina B; Tulpule A; Nathwani B
    Cancer; 2002 Mar; 94(5):1500-6. PubMed ID: 11920507
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Central nervous system involvement in indolent lymphomas.
    Spectre G; Gural A; Amir G; Lossos A; Siegal T; Paltiel O
    Ann Oncol; 2005 Mar; 16(3):450-4. PubMed ID: 15642707
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas.
    Nuutinen J; Leskinen S; Lindholm P; Söderström KO; Någren K; Huhtala S; Minn H
    Eur J Nucl Med; 1998 Jul; 25(7):729-35. PubMed ID: 9662595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Investigating the existence of quantum metabolic values in non-Hodgkin's lymphoma by 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography.
    Wong CY; Thie J; Parling-Lynch KJ; Zakalik D; Wong RH; Gaskill M; Margolis JH; Hill J; Sukari A; Chundru S; Fink-Bennett D; Nagle C
    Mol Imaging Biol; 2007; 9(1):43-9. PubMed ID: 17176979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Small Bowel Lymphoma.
    Rawls RA; Vega KJ; Trotman BW
    Curr Treat Options Gastroenterol; 2003 Feb; 6(1):27-34. PubMed ID: 12521569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.